The pre-clinical trial results of SolasCure’s Aurase Wound Gel, published in the International Wound Journal, < doi: https://doi.org/10.1111/iwj.14079 > showed preliminary evidence that supports its new enzymatic debridement product for use in chronic wounds. The enzyme is shown to have a good safety profile, both locally and systemically, which opens up a large therapeutic window. This has permitted SolasCure under regulatory review to test the enzyme on real patients with ulcers. SolasCure recently completed its CLEANVLU proof-of-concept first-in-man Phase IIa safety study examining the use of Aurase Wound Gel in chronic venous leg ulcer subjects. Results are now being collated and analysed, and more information will be available in the
The funding round was led by Seneca Partners and also included industry veterans, institutional venture and strategic investors, including BRAIN Biotech AG, EVA Pharma, Jonathan Milner, and Wealth Club.
Dr Sam Bakri, Founder & CEO, SolasCure, said: “We would like to thank investors in our Series B round for continuing to support us as we progress our clinical development programme and focus on developing the efficacy of Aurase Wound Gel. We are excited to be working with such an experienced team, whose specialist knowledge is greatly valued in our mission to support healthcare professionals with wound care products that significantly improve outcomes for patients with chronic wounds.”
SolasCure was founded in 2017 as a spin-off from BRAIN Biotech AG, a leading German biotech company.
For more information about SolasCure, visit: https://solascure.com/